Safety Reporting 2016 - Seminar on Best Practices for Safety Reporting in Clinical Trials for Drugs, Biologics and Medical Devices

Course "Best Practices for Safety Reporting in Clinical Trials for Drugs, Biologics and Medical Devices" has been pre-approved by RAPS as eligible for up to 12 credits towards a participant's RAC recertification upon full completion.
GlobalCompliancePanel Refer a Friend Program: Any Customer to 3 Referrals "Can Participate 2 Days Seminar for free of Cost.
Overview:
The Food and Drug Administration's Center for Drug Evaluation Research, Center for Biologics Evaluation Research and Center for Devices and Radiological Health are responsible for the approval of drug products, biologics and medical devices industries. This seminar begins with outlining the structural role of the FDA and a brief introduction to the Food, Drug and Cosmetic Act (the ACT) and how the FDA uses it to enforce the regulatory requirements during the drug, biologics and medical device approval process. Additionally, this seminar will highlight safety, which is in the FDA's mission statement, by guiding participants on how to develop a data safety monitoring plan and when it is important to use a Data Safety Monitoring Board. Additionally, various safety management practices will be discussed and the importance of creating a functional adverse event database. This seminar will also provide the terminology necessary to establish an adverse event monitoring score and the training requirements for study monitors will be discussed in detail. IND and IDE safety reports, IND annual safety updates and DSUR will be discussed. How to troubleshoot safety events with clinical site principal investigators and how to survive an FDA audit for safety management practices will complete the agenda for this seminar.
Why should you attend?
Since 1970 the regulations for conducting clinical trials has been under the direction of the Food and Drug Administration (FDA), more specifically, FDA's Center for Drug Evaluation and Research (CDER). CDER is the regulatory agency for drug applications, monitoring efficacy, safety and review process during all phases of clinical trials. As defined in its mission statement, "the FDA is responsible for protecting the public health by assuring the safety, efficacy and security of human and veterinary drugs, biological products, medical devices, our nation's food supply, cosmetics, and products that emit radiation." The history of clinical research involving humans introduced the Guidelines for Good Clinical Practice (GCP) for Trials on Pharmaceutical Products in 1995. GCP is the standard for the design, conduct, performance, monitoring, auditing, recording, analyses and reporting of clinical trial studies. These guidelines set the minimum quality standards for the conduct of clinical research. Compliance with GCP ensures that the rights, safety and well-being of study participants are protected.
Areas Covered in the Session:
Upon completing this course on the "Best Practices for Safety Reporting in Clinical Trials for Drugs, Biologics and Medical Devices" participants will:
? Have a knowledge of the role, structure what the Food and Drug Administration (FDA) regulates
? Learn the importance of the Food, Drug and Cosmetic Act (FDCA)
? Learn how to setup a data safety monitoring plan and when to use a data safety monitoring board
? Learn the various safety management practices employed during clinical studies
? Understand the importance of the training requirements of safety monitors (investigators)
? Discuss how to create an adverse event database
? Learn the submitting process for IND/IDE safety reporting
? Understand how to troubleshooting safety events with site principal investigators
? Learn how to survive an FDA audit for safety management practices and what Bioresearch Monitoring
Who Will Benefit:
This course is designed for people tasked with developing drug products, biologics and medical devices; and responsible for overseeing a company's clinical development program and regulatory strategies. This includes individuals responsible for overseeing regulatory affairs, developing strategies for establishing data safety monitoring plans, establishing adverse event databases, submitting timely safety reports to comply with regulatory compliance and those tasked with ensuring corporate compliance. Among others, this includes:
? Quality managers
? Quality professionals
? Regulatory professionals
? Compliance professionals
? Medical device professionals
? Biotechnology and pharmaceutical professionals
? Clinical Investigators
? Study Monitors
? Quality auditors
? Data analysis specialist
? Document control specialists
? Record retention specialists
? Medical affairs
? Marketing Staff
Agenda:
Day 1 Schedule:
Lecture 1:
Introduction to the FDA, Food, Drug and Cosmetic Act - Regulations and Guidance
? Role, Structure and Operations of the FDA
? Good Clinical Practice (GCP) in Clinical Trials
? Regulatory Agencies Involved in Clinical Development of Drug Products
Lecture 2:
Establishing and Importance of a Clinical Trial Safety Monitoring Plan
? Data Safety Monitoring Plan (DSMP) and Data Safety Monitoring Boards (DSMB)
? Who Requires What in Clinical Trials
? What is the Best Way to Monitor Your Clinical Trial
? Primary List of the Required Contents of DSMP
Lecture 3:
Outline of Various Safety Management Practices Employed in Clinical Trials
? Data Safety Monitoring Boards (What are they and when are they necessary)
? Data Monitoring Committees
? Institutional Review Boards (IRB) and Ethical Review Committees
? Investigator brochure
? Safety Assessment Committees
Lecture 4:
The Importance and Training Requirements for Safety Monitors for a Successful Clinical Trial
? General Information about a Clinical Monitor
? Duties in Specific Phases of Clinical Development
? Compliance Training on Good Clinical Practice (GCP), FDA Regulations and Guidelines
? Knowledge Specific to Site Study (SOPs, Protocols, Investigational Product)
? Site Specific Safety Monitoring
Lecture 5:
The Process in the Establishment of an Adverse Event Database
? Background
? Targeted Data Collection - Recommendations
? Circumstances in Which Targeted Data Collection Maybe Appropriate
? Method for Target or Selection Collection of Safety Data
? When Comprehensive Data Collection is Really Needed
? Types of Data That Should be Collected
Day 2 Schedule:
Lecture 1:
The Procedures and Requirements for Filing and Updating IND Safety Reports
? General Information about Investigational New Drug (IND) and Investigational Device Exemption (IDE)
? Mandatory Safety Reporting (IND - Initial and Follow up Reports)
? Monitoring the Safety Database and Submitting Safety Reports
? Submitting an IND Study
? Safety Reporting for Requirements for BA/BE Studies
? Review of Safety Information
Lecture 2:
Comprehensive Discussion on IDE Safety Reports with Medical Devices
? General Information on an Investigational Device Exemption (IDE)
? Mandatory Medical Device Reporting
? Responsibilities of Investigator-Sponsor Safety Reports in Clinical Trials
? Reporting Requirements for Manufacturers
? Reporting Requirements for Investigators
? MedSun: Shining a Light on Medical Products Safety
Lecture 3:
Safety Reporting for IND Annual Safety Update and Development Safety Update Report (DSUR)
? General Principles
? Relationship of DSUR to the Periodicity Safety Update Report
? Durations of DSUR Submissions
? Responsibilities for Preparing and Submitting a DSUR
? Guidance on Contents of a DSUR
? Significant Findings from Clinical Trials During the Reporting Periods
Lecture 4:
Troubleshooting Safety Events with Site Principle Investigators to Ensure Study Quality
? Background Information - FDA Guidance
? Overview of Clinical Investigator Responsibilities
? Supervision of the conduct of the Clinical Investigator
? Protecting the Rights, Safety and Welfare of Study Subjects
? Reporting Timeframes
? Types of Reportable Events
? Protocol Deviation - Major and Minor ones.
Lecture 5:
How to Prepare for an FDA Audit for Safety Management Practices
? Discuss legal obligations of FDA audits and Food Drug and Cosmetic Act
? Suggestion as to the steps clinical sites take to prepare for the FDA Inspector
? Bioresearch Monitoring or BIMO Inspection
? What is Form FDA 482?
? FDA inspection procedures
? Post-inspection procedures and importance of Form FDA 483
Speaker:
Harold Thibodeaux
Research Investigator, Stiefel
Harold Thibodeaux is a medical research scientist with in vivo pharmacological experiences in both academia and biopharmaceutical industry. During his prestigious career the focus of Mr. Thibodeaux's research efforts has been on the efficacy of cardiovascular drugs most notably Hypertension, Myocardial Infarction, Focal Ischemia (Stroke), Beyond Advair Pulmonary Research and topical antibiotics. Optimal therapeutic benefits were the goal in all of these projects but cardiovascular safety to provide safer medicines to patients was a priority. Mr. Thibodeaux transitioned into the pharmaceutical industry when he joined the Cardiovascular Department of Genentech in 1990, as a technical lead with the Second Generation TPA Project Team. Mr. Thibodeaux is a graduate from the College of Charleston with a Bachelor of Science Degree in biology and is a member of The Safety Pharmacology Society.
During his prestigious career, Harold Thibodeaux's ambition and innovation resulted in the successful clinical development of several novel drugs. As a young scientist with Genentech, his contributions to the Second Generation TPA Project were rewarded with the FDA approval of a thrombolytic drug (TNK-TPA or Tenectaplase) that was indicated for Acute Myocardial Infarction. Another notable achievement with the same project team was the approval of Activase Alterplase for Acute Ischemic Stroke Treatment.
As a scientist at Theravance, his innovative models of cardiovascular safety were instrumental in the formation of a Theravance/GlaxoSmithKline Partnership and the development of two clinical candidates for Chronic Obstructive Pulmonary Disease (COPD). Both drugs, BREO Ellipta and ANORO Ellipta, were approved by the FDA and are currently providing therapeutic benefits with patients with COPD.
In his role as an investigative scientist with Stiefel, a GlaxoSmithKline Company, Mr. Thibodeaux explored new medical research paths and using his many years of experience in the industry to support project efforts for the reformulations of topical antibiotics, development of models to study acne and writing protocols psoriasis.
During his years of academia and pharmaceutical industry provided an opportunity to authored 23 published articles and discussed his work with poster presentation at major scientific meetings. Harold is proud to have been a medical researcher in both academia and the biopharmaceutical industry and continues to support projects that lead to strategic partnerships that will develop novel drug pipelines for unmet medical needs and present webinars and seminars on drug development to assist pharmaceutical companies achieve their goals.
Location: Raleigh, NC Date: May 19th & 20th, 2016 Time: 9:00 AM to 6:00 PM
Venue: WILL BE ANNOUNCED SOON
Price: $1,295.00 (Seminar for One Delegate)
Register now and save $200. (Early Bird)
Until April 15, Early Bird Price: $1,295.00 from April 16 to May 17, Regular Price: $1,495.00
Quick Contact:
NetZealous DBA as GlobalCompliancePanel
Phone: 1-800-447-9407
Fax: 302-288-6884
Email: support-AT-globalcompliancepanel.com
Website: http://www.globalcompliancepanel.com/
Registration Link - http://bit.ly/Safety-Reporting-in-Clinical-Trials